机器人辅助根治性前列腺切除术与容积旋转调强放疗一线治疗局限性前列腺癌的比较
该回顾性研究纳入860例cT1-4N0M0局限性前列腺癌患者,分别接受机器人辅助根治性前列腺切除术(RARP,n=500)或容积旋转调强放疗(VMAT,n=360)。中位随访30和47.5个月,RARP组影像学无复发生存(rRFS)优于VMAT组,但多因素分析校正D'Amico风险分级、年龄校正Charlson合并症指数及同期雄激素剥夺治疗后,两者无显著差异。
要点
- RARP与VMAT的rRFS在中位随访后相似,多因素校正后无显著差异。
- 生化复发定义不同影响bRFS比较,统一标准后RARP组bRFS更优。
- 两组患者背景不同,需更长随访比较肿瘤特异性和总生存。
核心结论
- RARP与VMAT在中位随访后影像学无复发生存相似,尽管患者背景不同。
- 需更长时间随访比较两种技术的肿瘤特异性和总生存。
研究设计与样本
- 回顾性分析2011至2016年860例cT1-4N0M0前列腺癌患者,RARP组500例,VMAT组360例。
主要发现
- RARP组和VMAT组中位随访分别为30个月和47.5个月,中位年龄分别为67岁和71岁(均P<0.0001)。
- VMAT组bRFS显著优于RARP组,但生化复发定义不同。
- 统一生化复发定义(连续两次PSA≥0.2 ng/ml)后,RARP组bRFS显著优于VMAT组。
- RARP组rRFS显著优于VMAT组,但多因素分析校正D'Amico风险分级、年龄校正Charlson合并症指数及同期雄激素剥夺治疗后无显著差异。
关键数值与推荐
- 生化复发定义:RARP组为连续两次PSA≥0.2 ng/ml,VMAT组采用Phoenix定义。
- 统一生化复发定义:连续两次PSA≥0.2 ng/ml。
临床怎么用
- 对于局限性前列腺癌,RARP和VMAT均可作为一线治疗选择,影像学复发结局相似。
- 比较生化复发时需注意不同治疗方式的定义差异。
局限性
- 回顾性研究设计,两组患者年龄和随访时间存在显著差异。
- 随访时间中等,缺乏肿瘤特异性和总生存数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Although radical prostatectomy and external beam radiotherapy are recognized as comparable treatment options for localized prostate cancer, robot-assisted radical prostatectomy (RARP) and volumetric modulated arc therapy (VMAT) as the leading respective techniques have yet to be compared. METHODS: We retrospectively analyzed 860 patients with cT1-4N0M0 prostate cancer who underwent RARP (n = 500) or VMAT (n = 360) between 2011 and 2016. Biochemical recurrence-free survival (bRFS; two consecutive prostate-specific antigen measurements ≥0.2 ng/ml for RARP and Phoenix definition for VMAT) and radiological recurrence-free survival (rRFS; radiologically diagnosed distant metastasis or local recurrence) were compared between the two modalities. Cox proportional hazards model was used for multivariate analysis. RESULTS: The median follow-up durations were 30 and 47.5 months, and median ages were 67 and 71 years (both P < 0.0001) in the RARP and VMAT groups, respectively. VMAT patients had significantly better bRFS than RARP patients, though their definitions of biochemical recurrence differed. If a unified definition of biochemical recurrence (two consecutive prostate-specific antigen measurements ≥0.2 ng/ml) was applied, RARP patients had significantly better bRFS than VMAT patients. Regarding rRFS, RARP patients had significantly better outcomes than VMAT patients, however, multivariate analysis together with D'Amico's risk classification, age-adjusted Charlson's comorbidity index, and concomitant androgen-deprivation therapy, demonstrated no significant difference between RARP and VMAT. CONCLUSIONS: The rRFS outcomes of RARP and VMAT after a medium-term follow-up period were similar, despite their different patient backgrounds. Further studies with a longer follow-up period are needed to compare these techniques in terms of cancer-specific and overall survivals.
引用
- Taguchi S, Shiraishi K, Fujimura T, et al. Robot-assisted radical prostatectomy versus volumetric modulated arc therapy: Comparison of front-line therapies for localized prostate cancer. Radiother Oncol. 2019. PMID: 31176208. doi:10.1016/j.radonc.2019.05.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。